Supervivencia cáncer específica posterior a nefrectomía radical frente a nefrectomía parcial en carcinoma renal t2: revisión sistemática
| Contribuinte(s) |
Poveda Matiz, José Luis |
|---|---|
| Data(s) |
05/12/2013
|
| Resumo |
Introducción: El tratamiento estándar para los tumores renales localizados es la nefrectomía radical, sin embargo debido a la variación el tamaño del tumor renal en el momento del diagnóstico, se ha reemplazado en algunos casos por la nefrectomía parcial. Objetivo: Este estudio busca comparar el resultado oncológico de la nefrectomía parcial en términos de supervivencia cáncer específica, respecto a la nefrectomía radical, en pacientes mayores de 50 años con carcinoma renal estadio II (T2N0M0) Métodos: Se realizó una revisión sistemática de la literatura, con inclusión de estudios de casos y controles, cohortes y experimentos clínicos aleatorizados incluidos en las bases de datos de MEDLINE , EMBASE y CENTRAL Resultados: La búsqueda inicial emitió un total de 101 resultados, 11 artículos fueron preseleccionados y sólo un artículo cumplió con los criterios de selección; éste se clasificó como nivel de evidencia II. Conclusión: No fue posible concluir su equivalencia oncológica de la nefrectomía radical con la nefrectomía parcial, dado que no hay diseños de estudios que permitan llegar a esta conclusión. Introduction: Radical nephrectomy has been the standard procedure for the treatment of localized renal tumors However, partial nephrectomy is preferred in some cases due to the crescent diagnosis of small renal masses. Objective: The target of this study is to compare the oncological outcomes in patients older than 50 years with renal carcinoma stage II (T2N0M0) in therms of disease specific survival. In partial nephrectomy against radical nephrectomy. Methods: This Sistematic review was made by the assessment of the MEDLINE, EMBASE and CENTRAL databases with the inclusion of case-control studies, cohort studies and randomized controlled trials. Results: The initial search released 101 articles, 11 were preselected and one study were finally included with a II level of evidence. Conclusion: It was not possible to concluded the oncological equivalence between the radical nephrectomy and the partial nephrectomy, although there is not enough evidence. |
| Formato |
application/pdf |
| Identificador | |
| Idioma(s) |
spa |
| Publicador |
Facultad de Medicina |
| Direitos |
info:eu-repo/semantics/openAccess |
| Fonte |
instname:Universidad del Rosario reponame:Repositorio Institucional EdocUR De Castro J, McKiernan JM. Epidemiology Clinical Staging and Presentation of Renal Cell Carcinoma. Urol Clin N Am 2008;35:581–592 Sun M, Abdollah F, Bianchi M, et al. Treatment Management of Small Renal Masses in the 21st Century, A Paradigm Shift. Annals of Surgical Oncology in Press Harry W, Herr HW. Surgical Management of Renal Tumors: A Historical Perspective. Urol Clin N Am 2008;35:543–549 Becker F, Siemer S, Humke U, et al. Elective Nephron Sparing Surgery Should become Standard Treatment for Small Unilateral Renal Cell Carcinoma: Long-Term Survival Data of 216 Patients. Eur Urol 2006; 49:308–313 Touijer K, Jacqmin D, Kavoussi LR, et al. The Expanding Role of Partial Nephrectomy: A Critical Analysis of Indications, Results, and Complications. Eur Urol 2010;57:214–222 Go AS, Chertow GM, Fan D, el al. Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. The New England Journal of Medicine 2004;351:1296–1305 Heldwein FL, McCullough TC, Souto CA, et al. Localized Renal Cell Carcinoma Management: An Update. International Braz. J Urol 2006;34:676-690 Van Poppel H, Da Pozzo L, Albrecht W, et al. A Prospective, Randomised EORTC Intergroup Phase 3 Study Comparing the Oncologic Outcome of Elective Nephron-Sparing Surgery and Radical Nephrectomy for Low-Stage Renal Cell Carcinoma. Eur Urol 2011;59:543-552 Russo P. Deleterious Renal Functional Outcomes After Radical Nephrectomy. Eur Urol 2011;59: 340 - 341 Israel GM, Bosniak MA. An Update of the Bosniak Renal Cyst Classification System. Urology 2005; 66: 484-488 Smith AD, Remer EM, Cox KL. Bosniak Category IIF and III Cystic Renal Lesions: Outcomes and Associations. Radiology 2012; 262: 152-160 Warren KS, McFarlane J. The Bosniak Classification of Renal Cystic Masses. BJU 2005;95:939-942 Jemal A, Bray F, Center MM, et al. Global Cancer Statistics. CA Cancer J Clin 2011;61:69-90 Eble JN, Sauter G, Epstein JI, et al. In: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classification of Tumours 2004 Thariat J, Vendrely B, Roca S. Renal Involvement in Cancer and Renal Paraneoplastic Syndromes. Bull Cancer 2012;99:263-275 Edge SB, Byrd DR, Compton CC, et al. Cancer Staging Manual. AJCC 7th ed 2010;XV:649 Flanigan RC, Mickisch G, Sylvester R, et el. Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined Analysis. J Urol. 2004;171:1071-1076 Wein AJ. Campbell-Walsh Urology. – 10th ed. Saunders, an imprint of Elsevier Inc. 2012; Chap 49:1449 – 1452 Miller DC, Schonlau M, Litwin MS, Lai J, Saigal JC. Renal and Cardiovascular Morbidity After Partial or Radical Nephrectomy. Cancer 2008;112;511-520 Peycelon M, Hupertan V, Comperat E, et al. Longterm Outcomes After Nephron Sparing Surgery for Renal Cell Carcinoma Larger Than 4 cm. J Urol 2009;181:35 Leibovich BC, Blute ML, Cheville JC, et al. Nephron Sparing Surgery for Appropriately Selected Renal Cell Carcinoma Between 4 And 7 cm Results in Outcome Similar to Radical Nephrectomy. J Urol 2004;171:1066-1070 Patard JJ, Shvarts O, Lam JS, et al. Safety and Efficacy of Partial Nephrectomy for all T1 Tumors Based on an International Multicenter Experience. J Urol 2004;171:2181–2185,quiz 2435 Ficarra V, Novara G, Secco S et al. Preoperative Aspects And Dimensions Used For An Anatomical (PADUA) Classification Of Renal Tumours In Patients Who Are Candidates For Nephron-Sparing Surgery. Eur Urol 2009;56:786 Kutikov A, Uzzo RG. The R.E.N.A.L. Nephrometry Score: a Comprehensive Standardized System for Quantitating Renal Tumor Size, Location and Depth. J Urol 2009;182: 844 Simmons MN, Ching CB, Samplaski MK, Park CH, Gill IS. Kidney tumor location measurement using the C-Index method. J Urol 2010; 183:1798-1713 Hew MN, Baseskioglu B, Barwari K, et al. Critical Appraisal of the PADUA Classification and Assessment of the R.E.N.A.L. Nephrometry Score in Patients Undergoing Partial Nephrectomy. J Urol 2011;186:42-46 Badalato GM, Kates M, Wisnivesky JP, et al. Survival After Partial and Radical Nephrectomy for the Treatment of Stage T1bN0M0 Renal Cell Carcinoma (RCC) in the USA: A Propensity Scoring Approach. BJU Int 2011;109;1457- 1462 Kim SP, Murad MH, Thompson RH, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol 2012;188:51–7. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors—is there a difference in mortality and cardiovascular outcomes? J Urol 2009; 181:55–61 Weight CJ, Lieser G, Larson BT, et al. Partial Nephrectomy Is Associated with Improved Overall Survival Compared to Radical Nephrectomy in Patients with Unanticipated Benign Renal Tumours. Eur Urol 2010;58: 293-298 Klinghoffer Z, Tarride JE, Novara G, Ficarra V et al. Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. Canadian Urological Association Journal 2013;7:108-113. Karam JA, Wood CG. Management of Small Renal Masses: Watch, Cut, Freeze, or Fry. Eur Urol 2012;61:905–907 Mohammed A, Miller S, Douglas-Moore J, Miller M. Cryotherapy and its Applications in the Management of Urologic Malignancies: A Review of Its Use in Prostate and Renal Cancers. Urologic Oncology: Seminars and Original Investigations. Article in Press june 2013 Adamowicz J,Tworkiewicz J, Siekiera J, Drewa T. Ablative Therapies for Small Renal Tumors. Contemp Oncol 2013;17:24–28 Antonelli A, Cozzoli A, Simeone C, et al. Surgical Treatment of Adrenal Metastasis From Renal Cell Carcinoma: A Single-Centre Experience of 45 Patients. BJU Int 2006;97:505-508 González E, Martínez-Piñeiro L. Papel Actual de la Linfadenectomía y la Adrenalectomía en la Cirugía Radical del Cáncer Renal. Actas Urológicas Españolas 2009;33:562-568 Leibovich B, Blute M. Lymph Node Dissection in the Management of Renal Cell Carcinoma. Urol Clin N Am 2008;35:673–678 Kroog G, Motzer R. Systemic Therapy for Metastatic Renal Cell Carcinoma. Urol Clin N Am 2008;35:687–701 Herrmann E, Bierer S, Wülfing C. Update on Systemic Therapies of Metastatic Renal Cell Carcinoma. World J Urol 2010;28:303–309 Ljungberg B, Cowan NC, Hanbury DC, et al. EAU Guidelines on Renal Cell Carcinoma: The 2010 Update. Eur Urol 2010;58: 398-406 Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell Carcinoma. J Clin Oncol 2002;20:289–296 Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205–216. Kroeger N, Gajda N, Zanow J, et al. Downsizing a Tumor Thrombus of Advanced Renal Cell Carcinoma With Neoadjuvant Systemic Therapy and Resulting Histopathological Effects. Urol Int 2010; 84:479–484 Di Silverio F, Sciarra A, Parente U, Andrea A, et al. Neoadjuvant Therapy With Sorafenib in Advanced Renal Cell Carcinoma With Vena Cava Extension Submitted to Radical Nephrectomy. Urol Int 2008;80:451- 453 Karakiewicz PK, Suardi N, Jeldres C, Patard JJ, et al. Neoadjuvant Sutent Induction Therapy May Effectively Down-Stage Renal Cell Carcinoma Atrial Thrombi. Eur Urol 2008;53:845 -848 Bex A, Blank C, Meinhardt W, et al. A Phase II Study of Presurgical Sunitinib In Patients With Metastatic Clear-Cell Renal Carcinoma and the Primary Tumor In Situ. Urology 2011;78:832-837 Van Der Veldt AA, Meijerink MR, Van Den Eertwegh AJ, et al. Sunitinib for Treatment Of Advanced Renal Cell Cancer: Primary Tumor Response. Clinical Cancer Research 2008;14:2431–2436 Gorin MA, Ekwenna O, Soloway MS, Ciancio G. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery. Urology 2012;79:11 Bex A, Van Der Veldt AA, Blank C, Van Den Eertwegh AJ, et al. Neoadjuvant Sunitinib For Surgically Complex Advanced Renal Cell Cancer of Doubtful Resectability: Initial Experience With Downsizing to Reconsider Cytoreductive Surgery. World J Urol 2009;27:533–539 Ansari J, Doherty A, McCafferty I, et al. Neoadjuvant Sunitinib Facilitates Nephron-Sparing Surgery and Avoids Long-Term Dialysis in A Patient With Metachronous Contralateral Renal Cell Carcinoma. Clinical Genitourinary Cancer 2009; 2: E39–E41 Wood CG. The Role of Cytoreductive Nephrectomy in the Management of Metastatic Renal Cell Carcinoma. Urol Clin North Am 2003;30:581-588 Alt AL, Boorjian SA, et al. Survival After Complete Surgical Resection of Multiple Metastases From Renal Cell Carcinoma. Cancer 2011;117:2873-2882 Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, 2011 Moher D, Liberati A, Tetzlaff J and Altman DG. Reviews and Meta-Analyses: The PRISMA Statement. The PRISMA Group 2009. www.prisma-statement.org. Phillips B, Chris B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. November 1998. Updated Jeremy Howick. 2009 |
| Palavras-Chave | #CARCINOMA DE CÉLULAS RENALES #NEFRECTOMÍA #Renal Cell Carcinoma #Radical Nephrectomy #Partial Nephrectomy |
| Tipo |
info:eu-repo/semantics/bachelorThesis info:eu-repo/semantics/acceptedVersion |
